Sunday, 20 July 2025
28.4 C
Singapore
29.8 C
Thailand
17.1 C
Indonesia
28.4 C
Philippines

China Medical System seeks secondary listing on SGX to strengthen Southeast Asia presence

China Medical System seeks SGX listing to boost Southeast Asia expansion and commercialise innovative drugs through Singapore-based operations.

China Medical System Holdings Limited (CMS), a pharmaceutical platform company focused on linking drug innovation and commercialisation, has announced plans to pursue a secondary listing on the Mainboard of the Singapore Exchange (SGX) in July 2025. The move aims to enhance the company’s visibility and investor base in Southeast Asia, positioning Singapore as a key regional hub for its next growth phase.

CMS has been listed on the Main Board of the Hong Kong Stock Exchange (HKSE) since 2010 and is a constituent of the Hang Seng Large-Mid Cap (Investable) Index and Hang Seng Innovative Drug Index. The company brings nearly three decades of experience in China’s pharmaceutical industry, where it has developed strong capabilities in clinical demand-driven product identification, project management, and commercialisation. CMS also has in-house research and development operations that cover the full product lifecycle—from target selection and pre-clinical research to clinical development.

Building a regional pharmaceutical hub

Following years of success in China, CMS is expanding its footprint across Southeast Asia through its Singapore-headquartered business unit, Rxilient Health. Rxilient handles the licensing, registration, and commercialisation of pharmaceutical products in local markets, including Malaysia, Vietnam, the Philippines, Indonesia, and Thailand. As of 31 December 2024, Rxilient had built a portfolio of over ten differentiated products across therapeutic areas such as oncology, dermatology, central nervous system, gastroenterology, autoimmune conditions, and ophthalmology.

To support its regional expansion, CMS also established PharmaGend Global, a Contract Development and Manufacturing Organisation (CDMO) in Singapore. The facility spans 60,290 square metres and began commercial production in late 2024. It has a production capacity of one billion oral solid dosage tablets and capsules annually. Notably, the site is certified under the U.S. Food and Drug Administration’s Good Manufacturing Practice guidelines and has passed inspection by Singapore’s Health Sciences Authority.

Together, Rxilient and PharmaGend enable CMS to manage the full pharmaceutical value chain—research and development, manufacturing, and commercialisation—across Southeast Asia. This integrated setup supports the company’s goal to introduce more global, high-quality, and affordable drugs to patients in the region.

Shifting towards innovation-led growth

CMS is undergoing a strategic shift from generic drug sales towards a more innovation-driven business model. This transition follows challenges brought on by China’s Volume-based Procurement (VBP) policy, which has pressured prices and affected revenue from selected CMS products. The policy allows public hospitals to procure generics at significantly reduced prices through centralised bidding.

In response, CMS launched its Innovative Collaborative R&D strategy in 2017, followed by an In-house R&D strategy in 2021. These efforts have expanded the company’s pipeline to around 40 innovative drugs as of 31 December 2024. Five of these products have been approved for marketing in China, covering six medical indications, and have entered large-scale clinical use. These drugs are supported by CMS’s broad distribution network, which includes over 50,000 hospitals, medical institutions, and approximately 300,000 retail pharmacies across China.

The company expects continued growth from its innovation pipeline, which spans early to late clinical-stage products. In addition, its portfolio of exclusive and brand-name products has shown consistent performance, supporting overall business momentum.

Spotlight on ILUMETRI and future opportunities

One of CMS’s notable successes is the innovative biologic Tildrakizumab Injection (ILUMETRI), used to treat psoriasis. Approved in China in May 2023, ILUMETRI was added to the National Reimbursement Drug List (Category B1) by December of the same year and has since been rolled out to hospitals nationwide. It has received international recognition, featuring in psoriasis treatment guidelines in China, the United States, Europe, the United Kingdom, and Germany.

The company sees Southeast Asia as a key market, with nearly 700 million people and growing pharmaceutical demand driven by economic growth, an ageing population, and rising non-communicable disease prevalence. The SGX listing is expected to broaden CMS’s access to institutional investors in the region and reinforce its brand credibility to support long-term expansion plans.

CMS continues to position itself as a gateway for bringing global pharmaceutical innovations to Southeast Asia, using Singapore as a base for operations, manufacturing, and regional market development.

Hot this week

Microsoft is testing a smarter way to save your laptop’s battery on Windows 11

Microsoft is testing an adaptive energy saver in Windows 11 to boost battery life based on your device’s workload, rather than just its battery level.

Cyberpunk 2077 finally arrives on Macs this week

Cyberpunk 2077 arrives on Mac on July 17 with the Ultimate Edition, support for Apple Silicon, and Mac-exclusive features, including Spatial Audio.

Mercedes-Benz brings Microsoft Teams video calls to your car – even while driving

Mercedes-Benz now lets you join Microsoft Teams video calls using your in-car camera while driving, starting with the all-new CLA model.

imoo Watch Phone X10 review: Possibly the best kids’ smartwatch for families today

The imoo Watch Phone X10 is a smart, durable kids’ smartwatch with 4G, GPS, dual cameras, and safety features for everyday use.

Honor opens largest store in Singapore with hands-on access to Magic V5 foldable

Honor opens its biggest store in Singapore at Plaza Singapura, featuring the Magic V5 and exclusive launch-day promotions.

Nintendo opens larger Switch Online test to 40,000 participants

Nintendo invites 40,000 users to test a new Switch Online feature, expanding its mystery programme across more regions and both Switch models.

Xi Jinping raises concerns over China’s overinvestment in the EV and AI sectors

Xi Jinping warns against China's overinvestment in EVs and AI, urging officials to prioritise sustainability over short-term growth.

Meta refuses to sign the EU’s AI code of practice, citing legal concerns

Meta declines to sign the EU's AI Code of Practice, citing legal concerns and excessive requirements that exceed the scope of the AI Act.

Microsoft closes Movies & TV store on Xbox and Windows without warning

Microsoft has shut down its Movies & TV store on Xbox and Windows, ending new sales but maintaining access to previously purchased content.

Related Articles

Popular Categories